Final Analysis of the Prevention of Early Menopause Study (POEMS)/SWOG Intergroup S0230.

Moore HCF, Unger JM, Phillips KA, Boyle F, Hitre E, Moseley A, Porter DJ, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH and 13 more

Show all authors

Dakhil SR, Garcia AA, Gralow JR, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian LM, Meyskens FL, Gelber RD, Hortobagyi GN, Albain KS

Journal of the National Cancer Institute1 Feb 2019Cited by 68 (Europe PMC)

PMID30371800PMCIDPMC6657277DOI10.1093/jnci/djy185PepBankPUB-30371800

Source link PubMedAsk about this study

Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

01HumanRandomized controlled trialEfficacy outcome
In premenopausal hormone receptor-negative breast cancer, adding goserelin increased pregnancy incidence compared with chemotherapy alone.
In plain wordsIn premenopausal breast cancer, adding goserelin increased pregnancy incidence compared with chemotherapy alone.
Peptide
Goserelin
Outcome
IncreaseAt least one pregnancy
Study
n = 218
Comparator
Chemotherapy alone
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated
Measurements
Pregnancy incidence
23.1%
goserelin plus chemotherapy; 5 years; 95% CI 15.3-31.9
Pregnancy incidence
12.2%
chemotherapy; 5 years; 95% CI 6.8-19.2
Odds ratio
2.34
95% CI 1.07-5.11; P = .03
Source sentences
Summary
More patients in the chemotherapy + goserelin arm reported at least one pregnancy vs the chemotherapy arm (5-year cumulative incidence = 23.1%, 95% confidence interval [CI] = 15.3% to 31.9%; and 12.2%, 95% CI = 6.8% to 19.2%, respectively; odds ratio = 2.34; 95% CI = 1.07 to 5.11; P = .03).
2 context sentences(design, population, supporting numbers)
Summary · context
We evaluated long-term pregnancy and disease-related outcomes for patients in S0230/POEMS, a study in premenopausal women with stage I-IIIA estrogen receptor-negative, progesterone receptor-negative breast cancer to be treated with cyclophosphamide-containing chemotherapy.
Summary · context
Women were randomly assigned to standard chemotherapy with or without goserelin, a gonadotropin-releasing hormone agonist, and were stratified by age and chemotherapy regimen.
Report a problemFND-3037180001
02HumanRandomized controlled trialEfficacy outcome
In premenopausal hormone receptor-negative breast cancer, adding goserelin did not significantly improve disease-free survival versus chemotherapy alone.
In plain wordsIn premenopausal breast cancer, adding goserelin did not significantly improve disease-free survival compared with chemotherapy alone.
Peptide
Goserelin
Outcome
No significant changeDisease-free survival
Study
n = 218
Comparator
Chemotherapy alone
Outcome group
Tumor growth · Cancer
Studied dose
Dose not stated
Measurements
Hazard ratio
0.55
95% CI 0.27-1.10; P = .09
Source sentences
Summary
Randomization to goserelin + chemotherapy was associated with a nonstatistically significant improvement in disease-free survival (hazard ratio [HR] = 0.55; 95% CI = 0.27 to 1.10; P = .09)
2 context sentences(design, population, supporting numbers)
Summary · context
We evaluated long-term pregnancy and disease-related outcomes for patients in S0230/POEMS, a study in premenopausal women with stage I-IIIA estrogen receptor-negative, progesterone receptor-negative breast cancer to be treated with cyclophosphamide-containing chemotherapy.
Summary · context
Women were randomly assigned to standard chemotherapy with or without goserelin, a gonadotropin-releasing hormone agonist, and were stratified by age and chemotherapy regimen.
Report a problemFND-3037180002
03HumanRandomized controlled trialEfficacy outcome
In premenopausal hormone receptor-negative breast cancer, adding goserelin did not significantly improve overall survival versus chemotherapy alone.
In plain wordsIn premenopausal breast cancer, adding goserelin did not significantly improve survival compared with chemotherapy alone.
Peptide
Goserelin
Outcome
No significant changeOverall survival
Study
n = 218
Comparator
Chemotherapy alone
Outcome group
Mortality · Cancer
Studied dose
Dose not stated
Measurements
Hazard ratio
0.45
95% CI 0.19-1.04; P = .06
Source sentences
Summary
Randomization to goserelin + chemotherapy was associated with a nonstatistically significant improvement in disease-free survival (hazard ratio [HR] = 0.55; 95% CI = 0.27 to 1.10; P = .09) and overall survival (HR = 0.45; 95% CI = 0.19 to 1.04; P = .06).
2 context sentences(design, population, supporting numbers)
Summary · context
We evaluated long-term pregnancy and disease-related outcomes for patients in S0230/POEMS, a study in premenopausal women with stage I-IIIA estrogen receptor-negative, progesterone receptor-negative breast cancer to be treated with cyclophosphamide-containing chemotherapy.
Summary · context
Women were randomly assigned to standard chemotherapy with or without goserelin, a gonadotropin-releasing hormone agonist, and were stratified by age and chemotherapy regimen.
Report a problemFND-3037180003

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.